Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous CIK cells in advanced sarcoma
NCT03782363Phase 1Withdrawn
- Sponsor
- Italian Sarcoma Group
- Start
- Dec 2020
- Primary completion
- Apr 2023
- Modality
- Prophylactic Vaccines, Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous cytokine-induced killer cells in sarcoma (4 arms), sponsored by Italian Sarcoma Group. Primary endpoint: Incidence of dose-limiting toxicity at 6 weeks. Planned start Dec 2020; status: withdrawn.
02
Drugs
autologous cytokine-induced killer cells
03
Conditions
sarcoma
Beyond the preview
Go deeper on NCT03782363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03782363.